| 000 -LEADER |
|---|
| fixed length control field |
05084nam a22005175i 4500 |
| 001 - CONTROL NUMBER |
|---|
| control field |
978-3-540-27661-6 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
DE-He213 |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20161121230704.0 |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION |
|---|
| fixed length control field |
cr nn 008mamaa |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
100301s2005 gw | s |||| 0|eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9783540276616 |
| -- |
978-3-540-27661-6 |
| 024 7# - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
10.1007/3-540-27661-0 |
| Source of number or code |
doi |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER |
|---|
| Classification number |
RC681-688.2 |
| 072 #7 - SUBJECT CATEGORY CODE |
|---|
| Subject category code |
MJD |
| Source |
bicssc |
| 072 #7 - SUBJECT CATEGORY CODE |
|---|
| Subject category code |
MED010000 |
| Source |
bisacsh |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Classification number |
616.12 |
| Edition number |
23 |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
Atherosclerosis: Diet and Drugs |
| Medium |
[electronic resource] / |
| Statement of responsibility, etc. |
edited by Arnold von Eckardstein. |
| 246 3# - VARYING FORM OF TITLE |
|---|
| Title proper/short title |
with contributions by numerous experts |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
|---|
| Place of production, publication, distribution, manufacture |
Berlin, Heidelberg : |
| Name of producer, publisher, distributor, manufacturer |
Springer Berlin Heidelberg, |
| Date of production, publication, distribution, manufacture, or copyright notice |
2005. |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
XII, 816 p. |
| Other physical details |
online resource. |
| 336 ## - CONTENT TYPE |
|---|
| Content type term |
text |
| Content type code |
txt |
| Source |
rdacontent |
| 337 ## - MEDIA TYPE |
|---|
| Media type term |
computer |
| Media type code |
c |
| Source |
rdamedia |
| 338 ## - CARRIER TYPE |
|---|
| Carrier type term |
online resource |
| Carrier type code |
cr |
| Source |
rdacarrier |
| 347 ## - DIGITAL FILE CHARACTERISTICS |
|---|
| File type |
text file |
| Encoding format |
PDF |
| Source |
rda |
| 490 1# - SERIES STATEMENT |
|---|
| Series statement |
Handbook of Experimental Pharmacology, |
| International Standard Serial Number |
0171-2004 ; |
| Volume/sequential designation |
170 |
| 505 0# - FORMATTED CONTENTS NOTE |
|---|
| Formatted contents note |
Background -- The Pathogenesis of Atherosclerosis -- Risk Factors for Atherosclerotic Vascular Disease -- Metabolic Syndrome: Therapeutic Considerations -- The Impact of Diet -- Physical Activity, Obesity and Cardiovascular Diseases -- Fatty Acids and Atherosclerotic Risk -- Dietary Cholesterol, Atherosclerosis and Coronary Heart Disease -- Plant Sterols and Stanols -- Carbohydrates and Dietary Fiber -- Dietary Antioxidants and Paraoxonases Against LDL Oxidation and Atherosclerosis Development -- Soy, Isoflavones and Atherosclerosis -- Homocysteine and B Vitamins -- Alcohol -- Evidence-Based Anti-Atherosclerotic Drug Therapy -- Lipid and Non-lipid Effects of Statins -- Fibrates -- ACE Inhibitors and Angiotensin II Receptor Antagonists -- Inhibition of Platelet Activation and Aggregation -- Targets of Future Anti-Atherosclerotic Drug Therapy -- The ABC of Hepatic and Intestinal Cholesterol Transport -- Inhibition of the Synthesis of Apolipoprotein B-Containing Lipoproteins -- Therapy of Hyper-Lp(a) -- Modulation of High-Density Lipoprotein Cholesterol Metabolism and Reverse Cholesterol Transport -- Inhibition of Lipoprotein Lipid Oxidation -- Correction of Insulin Resistance and the Metabolic Syndrome -- Protection of Endothelial Function -- Modulation of Smooth Muscle Cell Proliferation and Migration: Role of Smooth Muscle Cell Heterogeneity -- Modulation of Macrophage Function and Metabolism -- Inflammation Is a Crucial Feature of Atherosclerosis and a Potential Target to Reduce Cardiovascular Events -- Autoimmune Mechanisms of Atherosclerosis -- Drug Therapies to Prevent Coronary Plaque Rupture and Erosion: Present and Future -- Reciprocal Role of Vasculogenic Factors and Progenitor Cells in Atherogenesis -- Gene Therapy of Atherosclerosis. |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
Cardiovascular diseases continue to be the leading cause of death in the - jority of industrialized countries. The most frequent underlying pathology, namely atherosclerosis, and its clinical sequelae, namely coronary heart d- ease, cerebrovascular disease and peripheral artery disease, remain common although for a long time we have been made aware of avoidable or mo- ?able etiological factors such as smoking, fat-rich diet or lack of exercise, and although these adverse lifestyle factors have been extensively addressed by population-wide primary prevention programs. Cardiovascular morbidity and mortality also remain high despite successful anti-hypertensive and lipid lowering drug therapies which help to reduce cardiovascular morbidity and mortality by about 30% in both secondary and tertiary prevention settings. This can partly be explained by the increasing life expectancy and growing p- portionofelderly people,especiallyinEuropeandNorthAmerica. Inaddition, the World Health Organization makes the alarming prediction that probably in response to the spreading of western dietary behavior and lack of exercise resulting in an increasing prevalence of diabetes, dyslipidemia and hypert- sion, cardiovascular diseases rather than infectious diseases will become the most frequent cause of death worldwide. This volume of the Handbook of Experimental Pharmacology entitled “Atherosclerosis” is divided into four parts and intends to give an overview on the pathogenesis of atherosclerosis, established treatment and prevention regimen, and of perspectives for the development of new treatment modalities. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Medicine. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Pharmacology. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Angiology. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Cardiology. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Metabolic diseases. |
| 650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Medicine & Public Health. |
| 650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Cardiology. |
| 650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Pharmacology/Toxicology. |
| 650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Angiology. |
| 650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Metabolic Diseases. |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Eckardstein, Arnold von. |
| Relator term |
editor. |
| 710 2# - ADDED ENTRY--CORPORATE NAME |
|---|
| Corporate name or jurisdiction name as entry element |
SpringerLink (Online service) |
| 773 0# - HOST ITEM ENTRY |
|---|
| Title |
Springer eBooks |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY |
|---|
| Relationship information |
Printed edition: |
| International Standard Book Number |
9783540225690 |
| 830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE |
|---|
| Uniform title |
Handbook of Experimental Pharmacology, |
| International Standard Serial Number |
0171-2004 ; |
| Volume/sequential designation |
170 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS |
|---|
| Uniform Resource Identifier |
http://dx.doi.org/10.1007/3-540-27661-0 |
| 912 ## - |
|---|
| -- |
ZDB-2-SBL |
